Compare HUIZ & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUIZ | APRE |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 10.8M |
| IPO Year | 2019 | 2019 |
| Metric | HUIZ | APRE |
|---|---|---|
| Price | $1.34 | $0.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.73 |
| AVG Volume (30 Days) | 31.0K | ★ 143.1K |
| Earning Date | 08-20-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.48 | N/A |
| Revenue Next Year | $6.59 | N/A |
| P/E Ratio | $7.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $0.55 |
| 52 Week High | $4.16 | $1.69 |
| Indicator | HUIZ | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 44.91 | 47.94 |
| Support Level | $1.17 | $0.70 |
| Resistance Level | $1.55 | $0.79 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 17.07 | 33.94 |
Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners. Geographically, the company is concentrated in PRC Mainland, Hong Kong and others segments.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.